Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22524250 | 0.95 | CCNB2 (0.40) | CCNB2CDK1CCNB1CCNB3LMNA | |
| SCHEMBL22524344 | 0.95 | CCNB2 (0.40) | CCNB2CDK1CCNB1CCNB3LMNA | |
| SCHEMBL22524343 | 0.90 | CCNB2 (0.43) | CCNB2CDK1CCNB1CCNB3LMNA | |
| SCHEMBL22524347 | 0.79 | CCNB2 (0.46) | CCNB2CDK1CCNB1CCNB3LMNA | |
| SCHEMBL22524348 | 0.78 | CCNB2 (0.45) | CCNB2CDK1CCNB1CCNB3LMNA | |
| SCHEMBL22524278 | 0.75 | PDE10A (0.37) | LMNAALDH1A1PDE10A | |
| SCHEMBL22524353 | 0.75 | CCNB2 (0.42) | CCNB2CDK1CCNB1CCNB3LMNA | |
| SCHEMBL22524350 | 0.74 | CSF1R (0.56) | LMNASMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL20119361 | 0.72 | SMN1; SMN2 (0.51) | CCNB2CDK1CCNB1CCNB3LMNA | |
| SCHEMBL17362591 | 0.70 | ALDH1A1 (0.36) | ALDH1A1HTTMAPTPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250276-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ, INC. (US) | 2025-08-07 | — | — | US | disclosed |
| US-20220162215-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ INC (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220162215-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ INC (US) | 2022-05-26 | — | — | US | disclosed |
| EP-3947390-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | Mitokinin, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-114026093-A | Compositions for treating neurodegenerative and mitochondrial diseases and methods of use thereof | 麦托吉宁公司 | 2022-02-08 | — | — | CN | disclosed |
| WO-2020206363-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ,INC. (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250276-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | PINK1, NLN, NME4 | CCNB2 4201/4885CDK1 1398/4885CCNB1 4172/4885 |
| US-20220162215-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, PINK1, NME4 | CCNB2 4201/4885CDK1 1441/4885CCNB1 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.